AbbVie (ABBV) Completes Acquisition of ImmunoGen (IMGN)
- Equities close slightly lower as focus shifts to data
- Zoom Video Communications guidance tops estimates following Q4 results beat
- Corporate profitability set to weaken - JPMorgan
- Global equities index sluggish with inflation in focus, oil climbs
- Nancy Pelosi buys Palo Alto Networks (PANW) call options, shares pop
"Together with ImmunoGen, we have the potential to continue redefining the standard of care for those living with cancer," said
ELAHERE® (mirvetuximab soravtansine-gynx) is the first and only antibody-drug conjugate (ADC) approved by the U.S. Food and Drug Administration (FDA) in ovarian cancer. The FDA granted accelerated approval for ELAHERE in folate receptor-alpha (FRα) positive platinum-resistant ovarian cancer (PROC) patients based on response data. Results from a confirmatory trial currently under review by the FDA show that ELAHERE is the first targeted agent to offer a survival benefit in PROC, with label expansion opportunities across larger segments of the ovarian cancer market.
ImmunoGen's follow-on pipeline of ADCs further builds on AbbVie's existing solid tumor pipeline of novel targeted therapies and next-generation immuno-oncology assets, which have the potential to create new treatment possibilities across multiple solid tumors and hematologic malignancies. Through focused R&D efforts, AbbVie has developed novel ADC technology and has unique strengths in antibody engineering, drug linker chemistry and toxin research. AbbVie and ImmunoGen's combined capabilities represent an opportunity to deliver potentially transformative ADC therapies to patients.
ImmunoGen's investigational Phase 1 asset, IMGN-151, is a next-generation FRα ADC for ovarian cancer with the potential for expansion into other solid tumor indications.
Pivekimab sunirine, currently in Phase 2, is an investigational anti-CD123 ADC targeting blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare blood cancer, which was granted FDA breakthrough therapy designation for the treatment of relapsed/refractory BPDCN.
For additional background on the acquisition, please read the announcement press release here and view AbbVie's investor presentation here.
AbbVie has acquired all outstanding ImmunoGen common stock for
Full-Year 2024 Outlook
AbbVie is reaffirming its previously issued 2024 full-year adjusted diluted EPS guidance range of
AbbVie is updating its previously issued 2024 first-quarter adjusted diluted EPS guidance range from
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Genmab (GMAB) FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab
- Dollar Tree (DLTR) and US DoJ Resolve Investigation into Operations in Arkansas
- Coliseum Capital Issues Letter to Board of R1 RCM (RCM) $13.75/sh Acquisition Offer
Create E-mail Alert Related CategoriesCorporate News, Guidance, Mergers and Acquisitions
Related EntitiesTwitter, Definitive Agreement, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!